Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Weishardt is a leading global producer of high-quality gelatin, fish collagen peptides, and texturizing systems for the food, pharmaceutical, and health industries. Founded in 1839 and headquartered in Graulhet, France, the company remains a family-owned business with a long-standing reputation for excellence in ingredient manufacturing. The company is particularly recognized for its Naticol brand, a range of bioactive fish collagen peptides used in nutraceuticals to promote skin health, joint mobility, and muscle mass. In the pharmaceutical sector, Weishardt supplies premium gelatin that meets strict pharmacopoeia standards for the production of hard and soft capsules. With manufacturing facilities across Europe and North America, the company emphasizes sustainable sourcing and advanced enzymatic hydrolysis technologies. Weishardt continues to invest in clinical research to validate the health benefits of its functional ingredients, supporting its position as a key partner in the global life sciences supply chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Weishardt Holding.